GUCY2C and colorectal carcinoma: Since the above molecular characterization results noted that the final BNC consisted of 30.91 μg/mL of anti-GCC mAb, which were successfully bound to 0.95 × 1015 AuNP-S-PEG5000-NH2 particles/mL, containing 35 μM of ZnPcS4 in PBS, it meant dilution was required because the PS PDT dose response assays indicated that the favorable ICD50 of ZnPcS4 PS post-PDT for CRC treatment was 0.125 μM.